Generics Global Industry Almanac 2017

Global Generics industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the global generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies.

– For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

– The market value is evaluated at ex-factory prices.

– Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.

– All currency conversions were calculated at constant average annual 2015 exchange rates.

– The global generics market is expected to generate total revenues of $318bn in 2016, representing a compound annual growth rate (CAGR) of 11.1% between 2012 and 2016.

– Market consumption volume is forecast to increase with a CAGR of 1.4% between 2012 and 2016, to reach a total of 78.6% of total pharma volume in 2016.

– The onset of the global economic crisis has led to several countries strengthening their generic policies. These policies have contributed to the strong growth experienced in this market in recent years.

Scope

– Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the global generics market

– Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global generics market

– Leading company profiles reveal details of key generics market players’ global operations and financial performance

– Add weight to presentations and pitches by understanding the future growth prospects of the global generics market with five year forecasts by both value and volume

Reasons to buy

- What was the size of the global generics market by value in 2016?

- What will be the size of the global generics market in 2021?

- What factors are affecting the strength of competition in the global generics market?

- How has the market performed over the last five years?

- Who are the top competitors in the global generics market?

Table of Contents

Table of Contents

EXECUTIVE SUMMARY

Market value

Market value forecast

Market volume

Market volume forecast

Geography segmentation

Introduction

What is this report about?

Who is the target reader?

How to use this report

Definitions

Global Generics

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Generics in Asia-Pacific

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Generics in Europe

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Generics in France

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Germany

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Australia

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Brazil

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Canada

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in China

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in India

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Indonesia

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Italy

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Japan

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Mexico

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in The Netherlands

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in North America

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Generics in Russia

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Scandinavia

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Generics in Singapore

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in South Africa

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in South Korea

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Spain

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Turkey

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in The United Kingdom

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in The United States

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Company Profiles

Leading companies

Appendix

Methodology

About MarketLine

List of Tables

List of Tables

Table 1: Global generics market value: $ billion, 201216

Table 2: Global generics market volume: % of total pharma volume, 201216

Table 3: Global generics market geography segmentation: $ billion, 2016

Table 4: Global generics market value forecast: $ billion, 201621

Table 5: Global generics market volume forecast: % of total pharma volume, 201621

Table 6: Asia-Pacific generics market value: $ billion, 201216

Table 7: AsiaPacific generics market volume: % of total pharma volume, 201216

Table 8: AsiaPacific generics market geography segmentation: $ billion, 2016

Table 9: Asia-Pacific generics market value forecast: $ billion, 201621

Table 10: AsiaPacific generics market volume forecast: % of total pharma volume, 201621

Table 11: Europe generics market value: $ billion, 201216

Table 12: Europe generics market volume: % of total pharma volume, 201216

Table 13: Europe generics market geography segmentation: $ billion, 2016

Table 14: Europe generics market value forecast: $ billion, 201621

Table 15: Europe generics market volume forecast: % of total pharma volume, 201621

Table 16: France generics market value: $ billion, 201216

Table 17: France generics market volume: % of total pharma volume, 201216

Table 18: France generics market geography segmentation: $ billion, 2016

Table 19: France generics market value forecast: $ billion, 201621

Table 20: France generics market volume forecast: % of total pharma volume, 201621

Table 21: France size of population (million), 201216

Table 22: France gdp (constant 2005 prices, $ billion), 201216

Table 23: France gdp (current prices, $ billion), 201216

Table 24: France inflation, 201216

Table 25: France consumer price index (absolute), 201216

Table 26: France exchange rate, 201216

Table 27: Germany generics market value: $ billion, 201216

Table 28: Germany generics market volume: % of total pharma volume, 201216

Table 29: Germany generics market geography segmentation: $ billion, 2016

Table 30: Germany generics market value forecast: $ billion, 201621

Table 31: Germany generics market volume forecast: % of total pharma volume, 201621

Table 32: Germany size of population (million), 201216

Table 33: Germany gdp (constant 2005 prices, $ billion), 201216

Table 34: Germany gdp (current prices, $ billion), 201216

Table 35: Germany inflation, 201216

Table 36: Germany consumer price index (absolute), 201216

Table 37: Germany exchange rate, 201216

Table 38: Australia generics market value: $ billion, 201216

Table 39: Australia generics market volume: % of total pharma volume, 201216

Table 40: Australia generics market geography segmentation: $ billion, 2016

Table 41: Australia generics market value forecast: $ billion, 201621

Table 42: Australia generics market volume forecast: % of total pharma volume, 201621

Table 43: Australia size of population (million), 201216

Table 44: Australia gdp (constant 2005 prices, $ billion), 201216

Table 45: Australia gdp (current prices, $ billion), 201216

Table 46: Australia inflation, 201216

Table 47: Australia consumer price index (absolute), 201216

Table 48: Australia exchange rate, 201216

Table 49: Brazil generics market value: $ billion, 201216

Table 50: Brazil generics market volume: % of total pharma volume, 201216

Table 51: Brazil generics market geography segmentation: $ billion, 2016

Table 52: Brazil generics market value forecast: $ billion, 201621

Table 53: Brazil generics market volume forecast: % of total pharma volume, 201621

Table 54: Brazil size of population (million), 201216

Table 55: Brazil gdp (constant 2005 prices, $ billion), 201216

Table 56: Brazil gdp (current prices, $ billion), 201216

Table 57: Brazil inflation, 201216

Table 58: Brazil consumer price index (absolute), 201216

Table 59: Brazil exchange rate, 201216

Table 60: Canada generics market value: $ billion, 201216

Table 61: Canada generics market volume: % of total pharma volume, 201216

Table 62: Canada generics market geography segmentation: $ billion, 2016

Table 63: Canada generics market value forecast: $ billion, 201621

Table 64: Canada generics market volume forecast: % of total pharma volume, 201621

Table 65: Canada size of population (million), 201216

Table 66: Canada gdp (constant 2005 prices, $ billion), 201216

Table 67: Canada gdp (current prices, $ billion), 201216

Table 68: Canada inflation, 201216

Table 69: Canada consumer price index (absolute), 201216

Table 70: Canada exchange rate, 201216

Table 71: China generics market value: $ billion, 201216

Table 72: China generics market volume: % of total pharma volume, 201216

Table 73: China generics market geography segmentation: $ billion, 2016

Table 74: China generics market value forecast: $ billion, 201621

Table 75: China generics market volume forecast: % of total pharma volume, 201621

Table 76: China size of population (million), 201216

Table 77: China gdp (constant 2005 prices, $ billion), 201216

Table 78: China gdp (current prices, $ billion), 201216

Table 79: China inflation, 201216

Table 80: China consumer price index (absolute), 201216

Table 81: China exchange rate, 201216

Table 82: India generics market value: $ billion, 201216

Table 83: India generics market volume: % of total pharma volume, 201216

Table 84: India generics market geography segmentation: $ billion, 2016

Table 85: India generics market value forecast: $ billion, 201621

Table 86: India generics market volume forecast: % of total pharma volume, 201621

Table 87: India size of population (million), 201216

Table 88: India gdp (constant 2005 prices, $ billion), 201216

Table 89: India gdp (current prices, $ billion), 201216

Table 90: India inflation, 201216

Table 91: India consumer price index (absolute), 201216

Table 92: India exchange rate, 201216

Table 93: Indonesia generics market value: $ billion, 201216

Table 94: Indonesia generics market volume: % of total pharma volume, 201216

Table 95: Indonesia generics market geography segmentation: $ billion, 2016

Table 96: Indonesia generics market value forecast: $ billion, 201621

Table 97: Indonesia generics market volume forecast: % of total pharma volume, 201621

Table 98: Indonesia size of population (million), 201216

Table 99: Indonesia gdp (constant 2005 prices, $ billion), 201216

Table 100: Indonesia gdp (current prices, $ billion), 201216

Table 101: Indonesia inflation, 201216

Table 102: Indonesia consumer price index (absolute), 201216

Table 103: Indonesia exchange rate, 201216

Table 104: Italy generics market value: $ billion, 201216

Table 105: Italy generics market volume: % of total pharma volume, 201216

Table 106: Italy generics market geography segmentation: $ billion, 2016

Table 107: Italy generics market value forecast: $ billion, 201621

Table 108: Italy generics market volume forecast: % of total pharma volume, 201621

Table 109: Italy size of population (million), 201216

Table 110: Italy gdp (constant 2005 prices, $ billion), 201216

Table 111: Italy gdp (current prices, $ billion), 201216

Table 112: Italy inflation, 201216

Table 113: Italy consumer price index (absolute), 201216

Table 114: Italy exchange rate, 201216

Table 115: Japan generics market value: $ billion, 201216

Table 116: Japan generics market volume: % of total pharma volume, 201216

Table 117: Japan generics market geography segmentation: $ billion, 2016

Table 118: Japan generics market value forecast: $ billion, 201621

Table 119: Japan generics market volume forecast: % of total pharma volume, 201621

Table 120: Japan size of population (million), 201216

Table 121: Japan gdp (constant 2005 prices, $ billion), 201216

Table 122: Japan gdp (current prices, $ billion), 201216

Table 123: Japan inflation, 201216

Table 124: Japan consumer price index (absolute), 201216

Table 125: Japan exchange rate, 201216

Table 126: Mexico generics market value: $ billion, 201216

Table 127: Mexico generics market volume: % of total pharma volume, 201216

Table 128: Mexico generics market geography segmentation: $ billion, 2016

Table 129: Mexico generics market value forecast: $ billion, 201621

Table 130: Mexico generics market volume forecast: % of total pharma volume, 201621

Table 131: Mexico size of population (million), 201216

Table 132: Mexico gdp (constant 2005 prices, $ billion), 201216

Table 133: Mexico gdp (current prices, $ billion), 201216

Table 134: Mexico inflation, 201216

Table 135: Mexico consumer price index (absolute), 201216

Table 136: Mexico exchange rate, 201216

Table 137: Netherlands generics market value: $ billion, 201216

Table 138: Netherlands generics market volume: % of total pharma volume, 201216

Table 139: Netherlands generics market geography segmentation: $ billion, 2016

Table 140: Netherlands generics market value forecast: $ billion, 201621

Table 141: Netherlands generics market volume forecast: % of total pharma volume, 201621

Table 142: Netherlands size of population (million), 201216

Table 143: Netherlands gdp (constant 2005 prices, $ billion), 201216

Table 144: Netherlands gdp (current prices, $ billion), 201216

Table 145: Netherlands inflation, 201216

Table 146: Netherlands consumer price index (absolute), 201216

Table 147: Netherlands exchange rate, 201216

Table 148: North America generics market value: $ billion, 201216

Table 149: North America generics market volume: % of total pharma volume, 201216

Table 150: North America generics market geography segmentation: $ billion, 2016

Table 151: North America generics market value forecast: $ billion, 201621

Table 152: North America generics market volume forecast: % of total pharma volume, 201621

Table 153: Russia generics market value: $ billion, 201216

Table 154: Russia generics market volume: % of total pharma volume, 201216

Table 155: Russia generics market geography segmentation: $ billion, 2016

Table 156: Russia generics market value forecast: $ billion, 201621

Table 157: Russia generics market volume forecast: % of total pharma volume, 201621

Table 158: Russia size of population (million), 201216

Table 159: Russia gdp (constant 2005 prices, $ billion), 201216

Table 160: Russia gdp (current prices, $ billion), 201216

Table 161: Russia inflation, 201216

Table 162: Russia consumer price index (absolute), 201216

Table 163: Russia exchange rate, 201216

Table 164: Scandinavia generics market value: $ billion, 201216

Table 165: Scandinavia generics market volume: % of total pharma volume, 201216

Table 166: Scandinavia generics market geography segmentation: $ billion, 2016

Table 167: Scandinavia generics market value forecast: $ billion, 201621

Table 168: Scandinavia generics market volume forecast: % of total pharma volume, 201621

Table 169: Singapore generics market value: $ billion, 201216

Table 170: Singapore generics market volume: % of total pharma volume, 201216

Table 171: Singapore generics market geography segmentation: $ billion, 2016

Table 172: Singapore generics market value forecast: $ billion, 201621

Table 173: Singapore generics market volume forecast: % of total pharma volume, 201621

Table 174: Singapore size of population (million), 201216

Table 175: Singapore gdp (constant 2005 prices, $ billion), 201216

Table 176: Singapore gdp (current prices, $ billion), 201216

Table 177: Singapore inflation, 201216

Table 178: Singapore consumer price index (absolute), 201216

Table 179: Singapore exchange rate, 201216

Table 180: South Africa generics market value: $ billion, 201216

Table 181: South Africa generics market volume: % of total pharma volume, 201216

Table 182: South Africa generics market geography segmentation: $ billion, 2016

Table 183: South Africa generics market value forecast: $ billion, 201621

Table 184: South Africa generics market volume forecast: % of total pharma volume, 201621

Table 185: South Africa size of population (million), 201216

Table 186: South Africa gdp (constant 2005 prices, $ billion), 201216

Table 187: South Africa gdp (current prices, $ billion), 201216

Table 188: South Africa inflation, 201216

Table 189: South Africa consumer price index (absolute), 201216

Table 190: South Africa exchange rate, 201216

Table 191: South Korea generics market value: $ billion, 201216

Table 192: South Korea generics market volume: % of total pharma volume, 201216

Table 193: South Korea generics market geography segmentation: $ billion, 2016

Table 194: South Korea generics market value forecast: $ billion, 201621

Table 195: South Korea generics market volume forecast: % of total pharma volume, 201621

Table 196: South Korea size of population (million), 201216

Table 197: South Korea gdp (constant 2005 prices, $ billion), 201216

Table 198: South Korea gdp (current prices, $ billion), 201216

Table 199: South Korea inflation, 201216

Table 200: South Korea consumer price index (absolute), 201216

Table 201: South Korea exchange rate, 201216

Table 202: Spain generics market value: $ billion, 201216

Table 203: Spain generics market volume: % of total pharma volume, 201216

Table 204: Spain generics market geography segmentation: $ billion, 2016

Table 205: Spain generics market value forecast: $ billion, 201621

Table 206: Spain generics market volume forecast: % of total pharma volume, 201621

Table 207: Spain size of population (million), 201216

Table 208: Spain gdp (constant 2005 prices, $ billion), 201216

Table 209: Spain gdp (current prices, $ billion), 201216

Table 210: Spain inflation, 201216

Table 211: Spain consumer price index (absolute), 201216

Table 212: Spain exchange rate, 201216

Table 213: Turkey generics market value: $ billion, 201216

Table 214: Turkey generics market volume: % of total pharma volume, 201216

Table 215: Turkey generics market geography segmentation: $ billion, 2016

Table 216: Turkey generics market value forecast: $ billion, 201621

Table 217: Turkey generics market volume forecast: % of total pharma volume, 201621

Table 218: Turkey size of population (million), 201216

Table 219: Turkey gdp (constant 2005 prices, $ billion), 201216

Table 220: Turkey gdp (current prices, $ billion), 201216

Table 221: Turkey inflation, 201216

Table 222: Turkey consumer price index (absolute), 201216

Table 223: Turkey exchange rate, 201216

Table 224: United Kingdom generics market value: $ billion, 201216

Table 225: United Kingdom generics market volume: % of total pharma volume, 201216

Table 226: United Kingdom generics market geography segmentation: $ billion, 2016

Table 227: United Kingdom generics market value forecast: $ billion, 201621

Table 228: United Kingdom generics market volume forecast: % of total pharma volume, 201621

Table 229: United Kingdom size of population (million), 201216

Table 230: United Kingdom gdp (constant 2005 prices, $ billion), 201216

Table 231: United Kingdom gdp (current prices, $ billion), 201216

Table 232: United Kingdom inflation, 201216

Table 233: United Kingdom consumer price index (absolute), 201216

Table 234: United Kingdom exchange rate, 201216

Table 235: United States generics market value: $ billion, 201216

Table 236: United States generics market volume: % of total pharma volume, 201216

Table 237: United States generics market geography segmentation: $ billion, 2016

Table 238: United States generics market value forecast: $ billion, 201621

Table 239: United States generics market volume forecast: % of total pharma volume, 201621

Table 240: United States size of population (million), 201216

Table 241: United States gdp (constant 2005 prices, $ billion), 201216

Table 242: United States gdp (current prices, $ billion), 201216

Table 243: United States inflation, 201216

Table 244: United States consumer price index (absolute), 201216

Table 245: United States exchange rate, 201215

Table 246: Allergan plc: key facts

Table 247: Allergan plc: key financials ($)

Table 248: Allergan plc: key financial ratios

Table 249: Mylan Inc.: key facts

Table 250: Mylan Inc.: key financials ($)

Table 251: Mylan Inc.: key financial ratios

Table 252: Sandoz International GmbH: key facts

Table 253: Teva Pharmaceutical Industries Limited: key facts

Table 254: Teva Pharmaceutical Industries Limited: key financials ($)

Table 255: Teva Pharmaceutical Industries Limited: key financial ratios

Table 256: Sun Pharmaceutical Industries Ltd.: key facts

Table 257: Sun Pharmaceutical Industries Ltd.: key financials ($)

Table 258: Sun Pharmaceutical Industries Ltd.: key financials (Rs.)

Table 259: Sun Pharmaceutical Industries Ltd.: key financial ratios

Table 260: Sanofi SA: key facts

Table 261: Sanofi SA: key financials ($)

Table 262: Sanofi SA: key financials (€)

Table 263: Sanofi SA: key financial ratios

Table 264: Les Laboratoires Servier: key facts

Table 265: STADA Arzneimittel AG: key facts

Table 266: STADA Arzneimittel AG: key financials ($)

Table 267: STADA Arzneimittel AG: key financials (€)

Table 268: STADA Arzneimittel AG: key financial ratios

Table 269: Aspen Pharmacare Holdings Ltd: key facts

Table 270: Aspen Pharmacare Holdings Ltd: key financials ($)

Table 271: Aspen Pharmacare Holdings Ltd: key financials (ZAR)

Table 272: Aspen Pharmacare Holdings Ltd: key financial ratios

Table 273: O Ache Laboratorios Farmaceuticos S.A.: key facts

Table 274: EMS Sigma Pharma: key facts

Table 275: Eurofarma Laboratórios S.A.: key facts

Table 276: Apotex, Inc.: key facts

Table 277: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts

Table 278: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)

Table 279: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)

Table 280: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios

Table 281: Aurobindo Pharma Limited: key facts

Table 282: Aurobindo Pharma Limited: key financials ($)

Table 283: Aurobindo Pharma Limited: key financials (Rs.)

Table 284: Aurobindo Pharma Limited: key financial ratios

Table 285: Cipla Limited: key facts

Table 286: Cipla Limited: key financials ($)

Table 287: Cipla Limited: key financials (Rs.)

Table 288: Cipla Limited: key financial ratios

Table 289: Lupin Limited: key facts

Table 290: Lupin Limited: key financials ($)

Table 291: Lupin Limited: key financials (Rs.)

Table 292: Lupin Limited: key financial ratios

Table 293: PT Kalbe Farma Tbk: key facts

Table 294: PT Kalbe Farma Tbk: key financials ($)

Table 295: PT Kalbe Farma Tbk: key financials (IDR)

Table 296: PT Kalbe Farma Tbk: key financial ratios

Table 297: PT Indofarma (Persero), Tbk: key facts

Table 298: PT Indofarma (Persero), Tbk: key financials ($)

Table 299: PT Indofarma (Persero), Tbk: key financials (IDR)

Table 300: PT Indofarma (Persero), Tbk: key financial ratios

Table 301: PT Sanbe Farma: key facts

Table 302: PT Soho Global Health: key facts

Table 303: Daiichi Sankyo Co., Ltd.: key facts

Table 304: Daiichi Sankyo Co., Ltd.: key financials ($)

Table 305: Daiichi Sankyo Co., Ltd.: key financials (Â¥)

Table 306: Daiichi Sankyo Co., Ltd.: key financial ratios

Table 307: Sawai Pharmaceutical Co., Ltd.: key facts

Table 308: Sawai Pharmaceutical Co., Ltd.: key financials ($)

Table 309: Sawai Pharmaceutical Co., Ltd.: key financials (Â¥)

Table 310: Sawai Pharmaceutical Co., Ltd.: key financial ratios

Table 311: Abbott Laboratories: key facts

Table 312: Abbott Laboratories: key financials ($)

Table 313: Abbott Laboratories: key financial ratios

Table 314: Krka, d. d., Novo mesto: key facts

Table 315: Krka, d. d., Novo mesto: key financials ($)

Table 316: Krka, d. d., Novo mesto: key financials (€)

Table 317: Krka, d. d., Novo mesto: key financial ratios

Table 318: Adcock Ingram Holdings Limited: key facts

Table 319: Adcock Ingram Holdings Limited: key financials ($)

Table 320: Adcock Ingram Holdings Limited: key financials (ZAR)

Table 321: Adcock Ingram Holdings Limited: key financial ratios

Table 322: Yuhan Corporation: key facts

Table 323: Yuhan Corporation: key financials ($)

Table 324: Yuhan Corporation: key financials (KRW)

Table 325: Yuhan Corporation: key financial ratios

Table 326: Esteve Group: key facts

Table 327: Abdi Ibrahim Ilac Sanayi ve Ticaret AS: key facts

Table 328: DEVA Holding: key facts

Table 329: DEVA Holding: key financials ($)

Table 330: DEVA Holding: key financials (TL)

Table 331: DEVA Holding: key financial ratios

Table 332: Nobel Pharmaceuticals: key facts

List of Figures

List of Figures

Figure 1: Global generics market value: $ billion, 201216

Figure 2: Global generics market volume: % of total pharma volume, 201216

Figure 3: Global generics market geography segmentation: % share, by value, 2016

Figure 4: Global generics market value forecast: $ billion, 201621

Figure 5: Global generics market volume forecast: % of total pharma volume, 201621

Figure 6: Forces driving competition in the global generics market, 2016

Figure 7: Drivers of buyer power in the global generics market, 2016

Figure 8: Drivers of supplier power in the global generics market, 2016

Figure 9: Factors influencing the likelihood of new entrants in the global generics market, 2016

Figure 10: Factors influencing the threat of substitutes in the global generics market, 2016

Figure 11: Drivers of degree of rivalry in the global generics market, 2016

Figure 12: Asia-Pacific generics market value: $ billion, 201216

Figure 13: AsiaPacific generics market volume: % of total pharma volume, 201216

Figure 14: AsiaPacific generics market geography segmentation: % share, by value, 2016

Figure 15: Asia-Pacific generics market value forecast: $ billion, 201621

Figure 16: AsiaPacific generics market volume forecast: % of total pharma volume, 201621

Figure 17: Forces driving competition in the generics market in Asia-Pacific, 2016

Figure 18: Drivers of buyer power in the generics market in Asia-Pacific, 2016

Figure 19: Drivers of supplier power in the generics market in Asia-Pacific, 2016

Figure 20: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2016

Figure 21: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2016

Figure 22: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2016

Figure 23: Europe generics market value: $ billion, 201216

Figure 24: Europe generics market volume: % of total pharma volume, 201216

Figure 25: Europe generics market geography segmentation: % share, by value, 2016

Figure 26: Europe generics market value forecast: $ billion, 201621

Figure 27: Europe generics market volume forecast: % of total pharma volume, 201621

Figure 28: Forces driving competition in the generics market in Europe, 2016

Figure 29: Drivers of buyer power in the generics market in Europe, 2016

Figure 30: Drivers of supplier power in the generics market in Europe, 2016

Figure 31: Factors influencing the likelihood of new entrants in the generics market in Europe, 2016

Figure 32: Factors influencing the threat of substitutes in the generics market in Europe, 2016

Figure 33: Drivers of degree of rivalry in the generics market in Europe, 2016

Figure 34: France generics market value: $ billion, 201216

Figure 35: France generics market volume: % of total pharma volume, 201216

Figure 36: France generics market geography segmentation: % share, by value, 2016

Figure 37: France generics market value forecast: $ billion, 201621

Figure 38: France generics market volume forecast: % of total pharma volume, 201621

Figure 39: Forces driving competition in the generics market in France, 2016

Figure 40: Drivers of buyer power in the generics market in France, 2016

Figure 41: Drivers of supplier power in the generics market in France, 2016

Figure 42: Factors influencing the likelihood of new entrants in the generics market in France, 2016

Figure 43: Factors influencing the threat of substitutes in the generics market in France, 2016

Figure 44: Drivers of degree of rivalry in the generics market in France, 2016

Figure 45: Germany generics market value: $ billion, 201216

Figure 46: Germany generics market volume: % of total pharma volume, 201216

Figure 47: Germany generics market geography segmentation: % share, by value, 2016

Figure 48: Germany generics market value forecast: $ billion, 201621

Figure 49: Germany generics market volume forecast: % of total pharma volume, 201621

Figure 50: Forces driving competition in the generics market in Germany, 2016

Figure 51: Drivers of buyer power in the generics market in Germany, 2016

Figure 52: Drivers of supplier power in the generics market in Germany, 2016

Figure 53: Factors influencing the likelihood of new entrants in the generics market in Germany, 2016

Figure 54: Factors influencing the threat of substitutes in the generics market in Germany, 2016

Figure 55: Drivers of degree of rivalry in the generics market in Germany, 2016

Figure 56: Australia generics market value: $ billion, 201216

Figure 57: Australia generics market volume: % of total pharma volume, 201216

Figure 58: Australia generics market geography segmentation: % share, by value, 2016

Figure 59: Australia generics market value forecast: $ billion, 201621

Figure 60: Australia generics market volume forecast: % of total pharma volume, 201621

Figure 61: Forces driving competition in the generics market in Australia, 2016

Figure 62: Drivers of buyer power in the generics market in Australia, 2016

Figure 63: Drivers of supplier power in the generics market in Australia, 2016

Figure 64: Factors influencing the likelihood of new entrants in the generics market in Australia, 2016

Figure 65: Factors influencing the threat of substitutes in the generics market in Australia, 2016

Figure 66: Drivers of degree of rivalry in the generics market in Australia, 2016

Figure 67: Brazil generics market value: $ billion, 201216

Figure 68: Brazil generics market volume: % of total pharma volume, 201216

Figure 69: Brazil generics market geography segmentation: % share, by value, 2016

Figure 70: Brazil generics market value forecast: $ billion, 201621

Figure 71: Brazil generics market volume forecast: % of total pharma volume, 201621

Figure 72: Forces driving competition in the generics market in Brazil, 2016

Figure 73: Drivers of buyer power in the generics market in Brazil, 2016

Figure 74: Drivers of supplier power in the generics market in Brazil, 2016

Figure 75: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2016

Figure 76: Factors influencing the threat of substitutes in the generics market in Brazil, 2016

Figure 77: Drivers of degree of rivalry in the generics market in Brazil, 2016

Figure 78: Canada generics market value: $ billion, 201216

Figure 79: Canada generics market volume: % of total pharma volume, 201216

Figure 80: Canada generics market geography segmentation: % share, by value, 2016

Figure 81: Canada generics market value forecast: $ billion, 201621

Figure 82: Canada generics market volume forecast: % of total pharma volume, 201621

Figure 83: Forces driving competition in the generics market in Canada, 2016

Figure 84: Drivers of buyer power in the generics market in Canada, 2016

Figure 85: Drivers of supplier power in the generics market in Canada, 2016

Figure 86: Factors influencing the likelihood of new entrants in the generics market in Canada, 2016

Figure 87: Factors influencing the threat of substitutes in the generics market in Canada, 2016

Figure 88: Drivers of degree of rivalry in the generics market in Canada, 2016

Figure 89: China generics market value: $ billion, 201216

Figure 90: China generics market volume: % of total pharma volume, 201216

Figure 91: China generics market geography segmentation: % share, by value, 2016

Figure 92: China generics market value forecast: $ billion, 201621

Figure 93: China generics market volume forecast: % of total pharma volume, 201621

Figure 94: Forces driving competition in the generics market in China, 2016

Figure 95: Drivers of buyer power in the generics market in China, 2016

Figure 96: Drivers of supplier power in the generics market in China, 2016

Figure 97: Factors influencing the likelihood of new entrants in the generics market in China, 2016

Figure 98: Factors influencing the threat of substitutes in the generics market in China, 2016

Figure 99: Drivers of degree of rivalry in the generics market in China, 2016

Figure 100: India generics market value: $ billion, 201216

Figure 101: India generics market volume: % of total pharma volume, 201216

Figure 102: India generics market geography segmentation: % share, by value, 2016

Figure 103: India generics market value forecast: $ billion, 201621

Figure 104: India generics market volume forecast: % of total pharma volume, 201621

Figure 105: Forces driving competition in the generics market in India, 2016

Figure 106: Drivers of buyer power in the generics market in India, 2016

Figure 107: Drivers of supplier power in the generics market in India, 2016

Figure 108: Factors influencing the likelihood of new entrants in the generics market in India, 2016

Figure 109: Factors influencing the threat of substitutes in the generics market in India, 2016

Figure 110: Drivers of degree of rivalry in the generics market in India, 2016

Figure 111: Indonesia generics market value: $ billion, 201216

Figure 112: Indonesia generics market volume: % of total pharma volume, 201216

Figure 113: Indonesia generics market geography segmentation: % share, by value, 2016

Figure 114: Indonesia generics market value forecast: $ billion, 201621

Figure 115: Indonesia generics market volume forecast: % of total pharma volume, 201621

Figure 116: Forces driving competition in the generics market in Indonesia, 2016

Figure 117: Drivers of buyer power in the generics market in Indonesia, 2016

Figure 118: Drivers of supplier power in the generics market in Indonesia, 2016

Figure 119: Factors influencing the likelihood of new entrants in the generics market in Indonesia, 2016

Figure 120: Factors influencing the threat of substitutes in the generics market in Indonesia, 2016

Figure 121: Drivers of degree of rivalry in the generics market in Indonesia, 2016

Figure 122: Italy generics market value: $ billion, 201216

Figure 123: Italy generics market volume: % of total pharma volume, 201216

Figure 124: Italy generics market geography segmentation: % share, by value, 2016

Figure 125: Italy generics market value forecast: $ billion, 201621

Figure 126: Italy generics market volume forecast: % of total pharma volume, 201621

Figure 127: Forces driving competition in the generics market in Italy, 2016

Figure 128: Drivers of buyer power in the generics market in Italy, 2016

Figure 129: Drivers of supplier power in the generics market in Italy, 2016

Figure 130: Factors influencing the likelihood of new entrants in the generics market in Italy, 2016

Figure 131: Factors influencing the threat of substitutes in the generics market in Italy, 2016

Figure 132: Drivers of degree of rivalry in the generics market in Italy, 2016

Figure 133: Japan generics market value: $ billion, 201216

Figure 134: Japan generics market volume: % of total pharma volume, 201216

Figure 135: Japan generics market geography segmentation: % share, by value, 2016

Figure 136: Japan generics market value forecast: $ billion, 201621

Figure 137: Japan generics market volume forecast: % of total pharma volume, 201621

Figure 138: Forces driving competition in the generics market in Japan, 2016

Figure 139: Drivers of buyer power in the generics market in Japan, 2016

Figure 140: Drivers of supplier power in the generics market in Japan, 2016

Figure 141: Factors influencing the likelihood of new entrants in the generics market in Japan, 2016

Figure 142: Factors influencing the threat of substitutes in the generics market in Japan, 2016

Figure 143: Drivers of degree of rivalry in the generics market in Japan, 2016

Figure 144: Mexico generics market value: $ billion, 201216

Figure 145: Mexico generics market volume: % of total pharma volume, 201216

Figure 146: Mexico generics market geography segmentation: % share, by value, 2016

Figure 147: Mexico generics market value forecast: $ billion, 201621

Figure 148: Mexico generics market volume forecast: % of total pharma volume, 201621

Figure 149: Forces driving competition in the generics market in Mexico, 2016

Figure 150: Drivers of buyer power in the generics market in Mexico, 2016

Figure 151: Drivers of supplier power in the generics market in Mexico, 2016

Figure 152: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2016

Figure 153: Factors influencing the threat of substitutes in the generics market in Mexico, 2016

Figure 154: Drivers of degree of rivalry in the generics market in Mexico, 2016

Figure 155: Netherlands generics market value: $ billion, 201216

Figure 156: Netherlands generics market volume: % of total pharma volume, 201216

Figure 157: Netherlands generics market geography segmentation: % share, by value, 2016

Figure 158: Netherlands generics market value forecast: $ billion, 201621

Figure 159: Netherlands generics market volume forecast: % of total pharma volume, 201621

Figure 160: Forces driving competition in the generics market in the Netherlands, 2016

Figure 161: Drivers of buyer power in the generics market in the Netherlands, 2016

Figure 162: Drivers of supplier power in the generics market in the Netherlands, 2016

Figure 163: Factors influencing the likelihood of new entrants in the generics market in the Netherlands, 2016

Figure 164: Factors influencing the threat of substitutes in the generics market in the Netherlands, 2016

Figure 165: Drivers of degree of rivalry in the generics market in the Netherlands, 2016

Figure 166: North America generics market value: $ billion, 201216

Figure 167: North America generics market volume: % of total pharma volume, 201216

Figure 168: North America generics market geography segmentation: % share, by value, 2016

Figure 169: North America generics market value forecast: $ billion, 201621

Figure 170: North America generics market volume forecast: % of total pharma volume, 201621

Figure 171: Forces driving competition in the generics market in North America, 2016

Figure 172: Drivers of buyer power in the generics market in North America, 2016

Figure 173: Drivers of supplier power in the generics market in North America, 2016

Figure 174: Factors influencing the likelihood of new entrants in the generics market in North America, 2016

Figure 175: Factors influencing the threat of substitutes in the generics market in North America, 2016

Figure 176: Drivers of degree of rivalry in the generics market in North America, 2016

Figure 177: Russia generics market value: $ billion, 201216

Figure 178: Russia generics market volume: % of total pharma volume, 201216

Figure 179: Russia generics market geography segmentation: % share, by value, 2016

Figure 180: Russia generics market value forecast: $ billion, 201621

Figure 181: Russia generics market volume forecast: % of total pharma volume, 201621

Figure 182: Forces driving competition in the generics market in Russia, 2016

Figure 183: Drivers of buyer power in the generics market in Russia, 2016

Figure 184: Drivers of supplier power in the generics market in Russia, 2016

Figure 185: Factors influencing the likelihood of new entrants in the generics market in Russia, 2016

Figure 186: Factors influencing the threat of substitutes in the generics market in Russia, 2016

Figure 187: Drivers of degree of rivalry in the generics market in Russia, 2016

Figure 188: Scandinavia generics market value: $ billion, 201216

Figure 189: Scandinavia generics market volume: % of total pharma volume, 201216

Figure 190: Scandinavia generics market geography segmentation: % share, by value, 2016

Figure 191: Scandinavia generics market value forecast: $ billion, 201621

Figure 192: Scandinavia generics market volume forecast: % of total pharma volume, 201621

Figure 193: Forces driving competition in the generics market in Scandinavia, 2016

Figure 194: Drivers of buyer power in the generics market in Scandinavia, 2016

Figure 195: Drivers of supplier power in the generics market in Scandinavia, 2016

Figure 196: Factors influencing the likelihood of new entrants in the generics market in Scandinavia, 2016

Figure 197: Factors influencing the threat of substitutes in the generics market in Scandinavia, 2016

Figure 198: Drivers of degree of rivalry in the generics market in Scandinavia, 2016

Figure 199: Singapore generics market value: $ billion, 201216

Figure 200: Singapore generics market volume: % of total pharma volume, 201216

Figure 201: Singapore generics market geography segmentation: % share, by value, 2016

Figure 202: Singapore generics market value forecast: $ billion, 201621

Figure 203: Singapore generics market volume forecast: % of total pharma volume, 201621

Figure 204: Forces driving competition in the generics market in Singapore, 2016

Figure 205: Drivers of buyer power in the generics market in Singapore, 2016

Figure 206: Drivers of supplier power in the generics market in Singapore, 2016

Figure 207: Factors influencing the likelihood of new entrants in the generics market in Singapore, 2016

Figure 208: Factors influencing the threat of substitutes in the generics market in Singapore, 2016

Figure 209: Drivers of degree of rivalry in the generics market in Singapore, 2016

Figure 210: South Africa generics market value: $ billion, 201216

Figure 211: South Africa generics market volume: % of total pharma volume, 201216

Figure 212: South Africa generics market geography segmentation: % share, by value, 2016

Figure 213: South Africa generics market value forecast: $ billion, 201621

Figure 214: South Africa generics market volume forecast: % of total pharma volume, 201621

Figure 215: Forces driving competition in the generics market in South Africa, 2016

Figure 216: Drivers of buyer power in the generics market in South Africa, 2016

Figure 217: Drivers of supplier power in the generics market in South Africa, 2016

Figure 218: Factors influencing the likelihood of new entrants in the generics market in South Africa, 2016

Figure 219: Factors influencing the threat of substitutes in the generics market in South Africa, 2016

Figure 220: Drivers of degree of rivalry in the generics market in South Africa, 2016

Figure 221: South Korea generics market value: $ billion, 201216

Figure 222: South Korea generics market volume: % of total pharma volume, 201216

Figure 223: South Korea generics market geography segmentation: % share, by value, 2016

Figure 224: South Korea generics market value forecast: $ billion, 201621

Figure 225: South Korea generics market volume forecast: % of total pharma volume, 201621

Figure 226: Forces driving competition in the generics market in South Korea, 2016

Figure 227: Drivers of buyer power in the generics market in South Korea, 2016

Figure 228: Drivers of supplier power in the generics market in South Korea, 2016

Figure 229: Factors influencing the likelihood of new entrants in the generics market in South Korea, 2016

Figure 230: Factors influencing the threat of substitutes in the generics market in South Korea, 2016

Figure 231: Drivers of degree of rivalry in the generics market in South Korea, 2016

Figure 232: Spain generics market value: $ billion, 201216

Figure 233: Spain generics market volume: % of total pharma volume, 201216

Figure 234: Spain generics market geography segmentation: % share, by value, 2016

Figure 235: Spain generics market value forecast: $ billion, 201621

Figure 236: Spain generics market volume forecast: % of total pharma volume, 201621

Figure 237: Forces driving competition in the generics market in Spain, 2016

Figure 238: Drivers of buyer power in the generics market in Spain, 2016

Figure 239: Drivers of supplier power in the generics market in Spain, 2016

Figure 240: Factors influencing the likelihood of new entrants in the generics market in Spain, 2016

Figure 241: Factors influencing the threat of substitutes in the generics market in Spain, 2016

Figure 242: Drivers of degree of rivalry in the generics market in Spain, 2016

Figure 243: Turkey generics market value: $ billion, 201216

Figure 244: Turkey generics market volume: % of total pharma volume, 201216

Figure 245: Turkey generics market geography segmentation: % share, by value, 2016

Figure 246: Turkey generics market value forecast: $ billion, 201621

Figure 247: Turkey generics market volume forecast: % of total pharma volume, 201621

Figure 248: Forces driving competition in the generics market in Turkey, 2016

Figure 249: Drivers of buyer power in the generics market in Turkey, 2016

Figure 250: Drivers of supplier power in the generics market in Turkey, 2016

Figure 251: Factors influencing the likelihood of new entrants in the generics market in Turkey, 2016

Figure 252: Factors influencing the threat of substitutes in the generics market in Turkey, 2016

Figure 253: Drivers of degree of rivalry in the generics market in Turkey, 2016

Figure 254: United Kingdom generics market value: $ billion, 201216

Figure 255: United Kingdom generics market volume: % of total pharma volume, 201216

Figure 256: United Kingdom generics market geography segmentation: % share, by value, 2016

Figure 257: United Kingdom generics market value forecast: $ billion, 201621

Figure 258: United Kingdom generics market volume forecast: % of total pharma volume, 201621

Figure 259: Forces driving competition in the generics market in the United Kingdom, 2016

Figure 260: Drivers of buyer power in the generics market in the United Kingdom, 2016

Figure 261: Drivers of supplier power in the generics market in the United Kingdom, 2016

Figure 262: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2016

Figure 263: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2016

Figure 264: Drivers of degree of rivalry in the generics market in the United Kingdom, 2016

Figure 265: United States generics market value: $ billion, 201216

Figure 266: United States generics market volume: % of total pharma volume, 201216

Figure 267: United States generics market geography segmentation: % share, by value, 2016

Figure 268: United States generics market value forecast: $ billion, 201621

Figure 269: United States generics market volume forecast: % of total pharma volume, 201621

Figure 270: Forces driving competition in the generics market in the United States, 2016

Figure 271: Drivers of buyer power in the generics market in the United States, 2016

Figure 272: Drivers of supplier power in the generics market in the United States, 2016

Figure 273: Factors influencing the likelihood of new entrants in the generics market in the United States, 2016

Figure 274: Factors influencing the threat of substitutes in the generics market in the United States, 2016

Figure 275: Drivers of degree of rivalry in the generics market in the United States, 2016

Figure 276: Allergan plc: revenues & profitability

Figure 277: Allergan plc: assets & liabilities

Figure 278: Mylan Inc.: revenues & profitability

Figure 279: Mylan Inc.: assets & liabilities

Figure 280: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 281: Teva Pharmaceutical Industries Limited: assets & liabilities

Figure 282: Sun Pharmaceutical Industries Ltd.: revenues & profitability

Figure 283: Sun Pharmaceutical Industries Ltd.: assets & liabilities

Figure 284: Sanofi SA: revenues & profitability

Figure 285: Sanofi SA: assets & liabilities

Figure 286: STADA Arzneimittel AG: revenues & profitability

Figure 287: STADA Arzneimittel AG: assets & liabilities

Figure 288: Aspen Pharmacare Holdings Ltd: revenues & profitability

Figure 289: Aspen Pharmacare Holdings Ltd: assets & liabilities

Figure 290: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability

Figure 291: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities

Figure 292: Aurobindo Pharma Limited: revenues & profitability

Figure 293: Aurobindo Pharma Limited: assets & liabilities

Figure 294: Cipla Limited: revenues & profitability

Figure 295: Cipla Limited: assets & liabilities

Figure 296: Lupin Limited: revenues & profitability

Figure 297: Lupin Limited: assets & liabilities

Figure 298: PT Kalbe Farma Tbk: revenues & profitability

Figure 299: PT Kalbe Farma Tbk: assets & liabilities

Figure 300: PT Indofarma (Persero), Tbk: revenues & profitability

Figure 301: Daiichi Sankyo Co., Ltd.: revenues & profitability

Figure 302: Daiichi Sankyo Co., Ltd.: assets & liabilities

Figure 303: Sawai Pharmaceutical Co., Ltd.: revenues & profitability

Figure 304: Sawai Pharmaceutical Co., Ltd.: assets & liabilities

Figure 305: Abbott Laboratories: revenues & profitability

Figure 306: Abbott Laboratories: assets & liabilities

Figure 307: Krka, d. d., Novo mesto: revenues & profitability

Figure 308: Krka, d. d., Novo mesto: assets & liabilities

Figure 309: Adcock Ingram Holdings Limited: revenues & profitability

Figure 310: Adcock Ingram Holdings Limited: assets & liabilities

Figure 311: Yuhan Corporation: revenues & profitability

Figure 312: Yuhan Corporation: assets & liabilities

Figure 313: DEVA Holding: revenues & profitability

Figure 314: DEVA Holding: assets & liabilities

    Pricing

Quick Buy
Add to basket Enquire before buying

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports